Genetic Signatures

Genetic Signatures Limited – Annual Report 2021 Sales progress Asia Pacific sales at at this stage primarily means Australia. This is Genetic Signatures’ home base and, as a consequence, the Company’s most mature market, Australia still accounts for the largest share of Genetic Signatures' sales globally. Australia has also been an early adopter of molecular testing methodologies, even though it only represents 1-2 per cent of the global molecular diagnostics testing market. Sales were boosted by the recurrence of outbreaks of COVID-19 and the resultant lockdowns in NSW and Victoria, our two largest markets. Naturally, these outbreaks resulted in increased demand for rapid testing for SARS-CoV-2. During the year new sites across Australia were added to the portfolio including the acquisition of the first Queensland laboratory as a client. Regulatory update In Australia, Genetic Signatures has four EasyScreen ™ detection kits listed on the Australian Register of Therapeutic Goods (ARTG) - SARS- CoV-2, respiratory, enteric and antimicrobial resistance (ESBL/CPO). The company has also lodged an application for its EasyScreen ™ STI/ Genital Pathogen Detection kit - registration has been delayed by COVID-19 but is anticipated soon. Asia Pacific Regions Commercialisation Update